Read the full text
Review and Position Paper By The Working Group For Cardiovascular Pharmacotherapy of The European Society Of Cardiology
Authors: Morten Schmidt, Morten Lamberts, Anne-Marie Schjerning Olsen, Emil Fosbøll, Alexander Niessner, Juan Tamargo, Giuseppe Rosano, Stefan Agewall, Juan Carlos Kaski, Keld Kjeldsen, Basil S. Lewis, Christian Torp-Pedersen
European Heart Journal - Cardiovascular Pharmacotherapy. doi: 10.1093/ehjcvp/pvv054 108-118. First published online: 16 March 2016
A joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis
Read the full text
Authors: Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, Torp-Pedersen C, Kjeldsen K, Lewis BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip GY, Verheugt FW, Agewall S.
Heart J. 2015 Dec 24. doi 10.1093/eurheartj/ehv676 First published online: 24 December 2015
A position document of the Working Group on Pharmacology and Drug Therapy of the ESC
Authors: Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, Drexel H, Patak A, Torp-Pedersen C, Kjeldsen KP, Tamargo J.
Eur Heart J. 2015 Oct 21;36(40):2677-80. doi: 10.1093/eurheartj/ehv161. First published online: 6 May 2015
Authors: Stefan Agewall1, Cattaneo, J.P. Collet, F. Andreotti, G.Y.H. Lip,F.W.A. Verheugt, K. Huber, E.L. Grove, J. Morais, S. Husted, S. Wassmann, G. Rosano, D. Atar1, A. Pathak, K. Kjeldsen, and R.F. Storey
Eur Heart J (2013) doi: 10.1093/eurheartj/eht042 First published online: February 20, 2013
Introduction: The ESC NSTEMI and STEMI guidelines1,2 and an ACCF/ACG/AHA consensus document3 recommend treatment with proton pump inhibitors (PPIs) in patients treated with dual antiplatelet treatment (DAPT) during the initial phase of an acute coronary syndrome (ACS) (ESC Class 1A recommendation), particularly in patients with a history of GI bleeding or peptic ulcer. Several studies have raised concerns that many PPIs, especially omeprazole, might diminish the antiplatelet effects of clopidogrel, most likely through inhibition of CYP2C19 and, consequently, the conversion of clopidogrel into its active metabolite. The aim of this position paper is to review the pharmacokinetic background of the interactions between these drugs, and their consequences on clinical outcomes, and to present suggestions for management of this important issue…
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved